Emma K. Accorsi

Medicine · Health Sciences

18h-index2.3kcitations48works85.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(14), Gut microbiota and health(11), Probiotics and Fermented Foods(11), Microbial Community Ecology and Physiology(10), COVID-19 Clinical Research Studies(9)

Publications48 total

Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
MMWR Morbidity and Mortality Weekly Report·2025· 85 citedOpen Access
Post-COVID conditions during Delta and early-Omicron SARS-CoV-2 variant periods among adults in the United States
2023Open Access
Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium
Inflammatory Bowel Diseases·2023· 3 citedOpen Access
<i>Notes from the Field:</i> Update on Pediatric Intracranial Infections — 19 States and the District of Columbia, January 2016–March 2023
MMWR Morbidity and Mortality Weekly Report·2023· 9 citedOpen Access
Effectiveness of Booster Doses of Monovalent mRNA COVID-19 Vaccine Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children, Adolescents, and Adults During Omicron Subvariant BA.2/BA.2.12.1 and BA.4/BA.5 Predominant Periods
Open Forum Infectious Diseases·2023· 12 citedOpen Access
Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023
MMWR Morbidity and Mortality Weekly Report·2023· 22 citedOpen Access
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023
MMWR Morbidity and Mortality Weekly Report·2023· 144 citedOpen Access
Post-COVID conditions and healthcare utilization among adults with and without disabilities—2021 Porter Novelli FallStyles survey
Disability and health journal·2022· 7 citedOpen Access
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022
MMWR Morbidity and Mortality Weekly Report·2022· 185 citedOpen Access
Pediatric Brain Abscesses, Epidural Empyemas, and Subdural Empyemas Associated with <i>Streptococcus</i> Species — United States, January 2016–August 2022
MMWR Morbidity and Mortality Weekly Report·2022· 35 citedOpen Access
Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
MMWR Morbidity and Mortality Weekly Report·2022· 85 citedOpen Access
Long-term diet and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection and Coronavirus Disease 2019 (COVID-19) severity
American Journal of Clinical Nutrition·2022· 28 citedOpen Access
Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron
New England Journal of Medicine·2022· 54 citedOpen Access
Discovery of bioactive microbial gene products in inflammatory bowel disease
Nature·2022· 90 citedOpen Access
Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance
JAMA·2022· 159 citedOpen Access
Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance
JAMA·2022· 88 citedOpen Access
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
JAMA·2022· 677 citedOpen Access
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in the staff of a public school system in the midwestern United States
PLoS ONE·2021· 16 citedOpen Access
Safety of administering biologics to IBD patients at an outpatient infusion center In New York City during the COVID-19 pandemic: Sars-CoV-2 seroprevalence and clinical and social characteristics
2021· 2 citedOpen Access
How to detect and reduce potential sources of biases in studies of SARS-CoV-2 and COVID-19
European Journal of Epidemiology·2021· 140 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Curtis Huttenhower(20), Marc Lipsitch(11), Kelsey N. Thompson(11), Sena Bae(11), Yancong Zhang(11), Hera Vlamakis(11), Jiaxian Shen(10), Eric A. Franzosa(10), Amadea Britton(9), Erica M. Hartmann(9), Tiffany Hsu(9), Regina Joice Cordy(9), Ayala Maayan‐Metzger(9), Hanaa Jaber(9), Aylana Reiss-Mandel(9), Madeleine Kline(9), Casey DuLong(9), Gili Regev‐Yochay(9), Katherine E. Fleming-Dutra(8), Zachary Smith(8)